ITM Isotopen Technologien München AG is a privately owned biotechnology and radiopharmaceutical group of companies dedicated to the development, production and global supply of targeted diagnostic and therapeutic radiopharmaceuticals and radioisotopes for use in cancer treatment.
Since its foundation in 2004, ITM and its subsidiaries have established GMP manufacturing and a robust global supply network of innovative, first-in-class medical radioisotopes and generator platforms for a new generation of targeted cancer diagnostics and therapies.
Furthermore, ITM is developing a proprietary portfolio and growing Precision Oncology Pipeline of targeted treatments in various stages of clinical development, which address a range of cancers such as neuroendocrine tumors, glioblastoma, osteosarcoma and bone metastases, as well as folate receptor α positive tumors such as lung, ovarian or breast cancer.
As Nukleon, we serve as the authorized distributor of ITM for high efficiency nonGMP or GMP grade Ge-68/Ga-68 Generator, highly pure and no-carrier-added EndolucinBeta® (n.c.a. Lutesyum-177), user-friendly iQS-TS synthesis device and all its accessories, which perform synthesis operations in 17 minutes in totally, including elution, I-125 labeled eye, prostate and brain seeds and Ru-106 eye plaque in the Turkish market.
For more information, you can visit the link www.itm.ag